Published data from tirzepatide withdrawal studies indicate that a significant proportion of lost weight is regained within 12 months of stopping treatment, consistent with the broader pattern observed across the GLP-1 class
You want to apply the patch to a clean, dry, hairless area of skin
They differ only in available doses and packaging
Who is Retatrutide 40 mg for Retatrutide is an investigational drug (Phase 3), not yet approved by the FDA/EMA Triple GLP-1 / GIP / glucagon agonist a unique mechanism of action For patients for whom single (Ozempic) or dual (Mounjaro) agonists did not deliver enough effect Strictly under medical supervision Retatrutide 40 mg compared to other doses Retatrutide 12 mg showed ~24% weight loss over 48 weeks (Phase 2, NEJM 2023) Compared to Mounjaro 15 mg (~2226%) a similar effect, but with a triple mechanism Key difference: retatrutide activates the glucagon receptor, increasing energy expenditure No final Phase 3 results yet efficacy and safety are still being confirmed FAQ about Retatrutide 40 mg (ALLUVI) 1 ALLUVI Retatrutide injection pen (40 mg total, dial mechanism up to 10 mg per dose), 12 single-use ALLUVI needles and dosing instructions (Dosage Guide) with step-by-step schedule from 2.5 mg to 10 mg
This disconnect between physical health and aesthetic outcomes is what makes Ozempic face a concern for so many
For many patients, compounded GLP-1 tablets offer similar benefits in terms of appetite suppression and glucose regulation when dosed properly
